New approaches in cancer therapy that facilitate selective targeting of cancers have been emerging in recent years. Apoptin represents a new anti-cancer tool in such new approaches with great potentials. Two routes can be taken using Apoptin or its encoding cDNA, i.e. as protein therapy or gene therapy.
A research article to be published on 21 June 2008, in the World Journal of Gastroenterology addresses this question. The research team led by Prof. Duan from Life Sciences Institute of Northwest University used molecular biology,to generated a cDNA construct of SP-Tat-Apoptin fusion. Cancer cells transfected with this construct would express the recombinant Apoptin and apoptosis would be induced in them. By incorporating a synthetic signal peptide authors also expected Apoptin to be secreted outside of the transfected cells as Tat-Apoptin fusion protein and re-enter adjacent untransfected HepG2 cells, enabling the construct to act as both protein and gene therapeutic agent and increasing the potency of Apoptin in cancer therapy.
Having a synthetic signal peptide, the recombinant Apoptin was able to be secreted outside of the transfected cells and re-enter adjacent untransfected HepG2 cells. The recombinant protein was detected in the cytoplasm in HepG2 and HUVEC cells shortly after co-culture of the cells with the cell-free supernatant of the transfected CHO cell culture, indicating the secreted Tat-Apoptin fusion protein contained in the CHO cell culture media was able to enter these cells. The fusion protein was later found in the nucleus in HepG2 cells and induced HepG2 cell apoptosis.
The new secretory characteristic increased the possibility of Apoptin being used in cancer gene therapy. However, there are still a large number of unanswered questions regarding the mechanisms and therapeutic usage of Apoptin, and further studies are certainly required.
There are more HCC cell line used to confirm the results in our study, for example, Bel-7402 HCC cell line. The result about Bel-7402 will be discussed in future. Meanwhile in HUVEC cells, SP-Tat-Apoptin remained in the cytoplasm and no induction of apoptosis above the background level was observed.
Reference: Han SX, Ma JL, Lv Y, Huang C, Liang HH, Duan KM. Secretory Tat-Apoptin fusion protein induces apoptosis in hepatocellular carcinoma HepG2 cells. World J Gastroenterol 2008; 14(23): 3642-3649
Correspondence to: Kang-Min Duan, College of Life Sciences, Northwest University, 229 Taibai Rd. North, Xi'an 710069, Shaanxi Province, China. email@example.com
Telephone: +86-29-88302132 Fax: +86-28-88305288
About World Journal of Gastroenterology
World Journal of Gastroenterology (WJG), a leading international journal in gastroenterology and hepatology, has established a reputation for publishing first class research on esophageal cancer, gastric cancer, liver cancer, viral hepatitis, colorectal cancer, and H pylori infection and provides a forum for both clinicians and scientists. WJG has been indexed and abstracted in Current Contents/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch) and Journal Citation Reports/Science Edition, Index Medicus, MEDLINE and PubMed, Chemical Abstracts, EMBASE/Excerpta Medica, Abstracts Journals, Nature Clinical Practice Gastroenterology and Hepatology, CAB Abstracts and Global Health. ISI JCR 2003-2000 IF: 3.318, 2.532, 1.445 and 0.993. WJG is a weekly journal published by WJG Press. The publication dates are the 7th, 14th, 21st, and 28th day of every month. WJG is supported by The National Natural Science Foundation of China, No. 30224801 and No. 30424812, and was founded with the name of China National Journal of New Gastroenterology on October 1, 1995, and renamed WJG on January 25, 1998.
About The WJG Press
The WJG Press mainly publishes World Journal of Gastroenterology.